Modality
mRNA
MOA
PARPi
Target
CD38
Pathway
RAS/MAPK
EoETTR Amyloidosis
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
→ Feb 2025
Phase 2Current
NCT07470998
2,007 pts·EoE
2021-01→2025-02·Terminated
2,007 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-031.2y agoPh2 Data· EoE
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
P2
Termina…
Catalysts
Ph2 Data
2025-02-03 · 1.2y ago
EoE
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07470998 | Phase 2 | EoE | Terminated | 2007 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |